Cardiogenic shock: therapeutic implications of altered myocardial energy balance.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000332:Aerobiosis; D000693:Anaerobiosis; D000804:Angiotensin II / Q000627:therapeutic use; D001243:Assisted Circulation; D001794:Blood Pressure; D002302:Cardiac Output; D003326:Coronary Circulation; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004554:Electric Countershock; D004837:Epinephrine / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006321:Heart / Q000503:physiopathology*; D006334:Heart Function Tests; D006339:Heart Rate; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008680:Metaraminol / Q000627:therapeutic use; D009119:Muscle Contraction; D009206:Myocardium / Q000378:metabolism*; D009638:Norepinephrine / Q000627:therapeutic use; D010101:Oxygen Consumption; D010138:Pacemaker, Artificial; D011433:Propranolol / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy
D000317:Adrenergic alpha-Antagonists; D004071:Digitalis Glycosides; D005938:Glucocorticoids; D000804:Angiotensin II; D008680:Metaraminol; D005934:Glucagon; D011433:Propranolol; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine